vTv Therapeutics (VTVT) Competitors $22.10 +0.29 (+1.31%) Closing price 03:58 PM EasternExtended Trading$21.68 -0.41 (-1.88%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. CADL, SCPH, TKNO, SOPH, NMRA, ALLO, JBIO, TECX, ABEO, and GALTShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Candel Therapeutics (CADL), scPharmaceuticals (SCPH), Alpha Teknova (TKNO), SOPHiA GENETICS (SOPH), Neumora Therapeutics (NMRA), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Tectonic Therapeutic (TECX), Abeona Therapeutics (ABEO), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Its Competitors Candel Therapeutics scPharmaceuticals Alpha Teknova SOPHiA GENETICS Neumora Therapeutics Allogene Therapeutics Jade Biosciences Tectonic Therapeutic Abeona Therapeutics Galectin Therapeutics Candel Therapeutics (NASDAQ:CADL) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Do analysts rate CADL or VTVT? Candel Therapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 235.01%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 60.67%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is CADL or VTVT more profitable? Candel Therapeutics' return on equity of -41.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -41.00% -26.81% vTv Therapeutics N/A -179.75%-55.91% Which has stronger earnings & valuation, CADL or VTVT? vTv Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel TherapeuticsN/AN/A-$55.18M-$0.69-8.65vTv Therapeutics$1.02M85.35-$18.46M-$3.12-7.08 Does the media prefer CADL or VTVT? In the previous week, Candel Therapeutics had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 10 mentions for Candel Therapeutics and 5 mentions for vTv Therapeutics. Candel Therapeutics' average media sentiment score of 0.55 beat vTv Therapeutics' score of 0.50 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, CADL or VTVT? Candel Therapeutics has a beta of -0.94, meaning that its stock price is 194% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Do institutionals and insiders have more ownership in CADL or VTVT? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 1.3% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCandel Therapeutics beats vTv Therapeutics on 10 of the 15 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.05M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-7.0822.9285.4427.36Price / Sales85.35270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book4.9310.5512.426.82Net Income-$18.46M-$52.58M$3.32B$276.89M7 Day Performance0.11%1.09%1.01%0.27%1 Month Performance8.26%16.09%10.75%8.31%1 Year Performance65.63%18.41%76.20%35.60% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics1.7416 of 5 stars$22.10+1.3%$35.50+60.7%+66.9%$87.05M$1.02M-7.089Analyst ForecastCADLCandel Therapeutics2.2802 of 5 stars$5.47-1.6%$20.00+265.6%-3.7%$305.22M$120K-7.9360News CoverageSCPHscPharmaceuticals4.0373 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330High Trading VolumeTKNOAlpha Teknova2.2337 of 5 stars$5.65+0.2%$10.00+77.0%-17.5%$301.83M$37.74M-13.45240SOPHSOPHiA GENETICS2.282 of 5 stars$4.05-8.0%$8.00+97.5%+25.1%$297.35M$65.17M-9.20520High Trading VolumeNMRANeumora Therapeutics2.1061 of 5 stars$1.89+3.3%$7.14+277.9%-88.5%$296.36MN/A-1.20108News CoverageALLOAllogene Therapeutics2.5842 of 5 stars$1.38+3.8%$8.44+511.9%-53.2%$295.10M$20K-1.24310Analyst DowngradeJBIOJade Biosciences2.5247 of 5 stars$9.14+3.2%$16.00+75.1%N/A$289.07MN/A-0.3020TECXTectonic Therapeutic2.8224 of 5 stars$15.20-0.3%$80.29+428.2%-52.3%$285.17MN/A-3.76120ABEOAbeona Therapeutics4.4 of 5 stars$5.34-1.3%$19.50+265.2%-14.7%$277.42M$400K7.6390Analyst ForecastGALTGalectin Therapeutics1.1911 of 5 stars$4.44+2.5%$6.00+35.1%+88.6%$277.38MN/A-6.949 Related Companies and Tools Related Companies CADL Alternatives SCPH Alternatives TKNO Alternatives SOPH Alternatives NMRA Alternatives ALLO Alternatives JBIO Alternatives TECX Alternatives ABEO Alternatives GALT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
